spec sheet6 rows
Uro-Vaxom is an oral capsule of freeze dried lysate from eighteen killed Escherichia coli strains, taken daily for three months to reduce the frequency of recurrent urinary tract infections.
- Fewer recurrent urinary tract infections over a three month course
- The oral immunostimulant mainstream urology actually takes seriously
- An alternative to another round of antibiotics
- Freeze dried lysate of eighteen killed Escherichia coli strains
- Raises mucosal IgA through gut lymphoid tissue
- Uro-Vaxom is OM-89: lyophilised immunostimulating fractions from 18 uropathogenic Escherichia coli strains, taken orally as a capsule; it is a bacterial lysate immunotherapy, not an antibiotic and not a conventional vaccine [3].
- The favourable meta-analysis found a mean 39% reduction in the number of UTIs across about 5 trials and 1,000 adult patients over 6-12 months of observation, with reduced antibacterial use, and noted that OM-89 was the only immunotherapeutic product in this space with studies meeting contemporary standards [1].
- The sceptical meta-analysis is the one that matters for an honest entry: of 15 double-blind randomised trials identified, 10 were excluded for methodological flaws, and the 5 usable studies (396 vs 392 patients) had no adequate methodology description, no conflict-of-interest or industry-commitment declarations, unclear allocation concealment in two, and 137 dropouts. All 5 favoured the vaccine, but the authors conclude the literature is 'of low quality', limited to 6 months, with variable UTI definitions and publication bias that could not be excluded [2].
- The immunological mechanism is well characterised in animals and in vitro: oral dosing induces E. coli-specific serum IgA and IgG, raises total IgA, activates macrophages and delays neutrophil apoptosis (PMID 9296288, PMID 20648922).
- OM-89 is authorised in much of Europe and is recommended by EAU guidelines as an option for recurrent UTI prophylaxis in women. It is not FDA-approved in the United States.
Mechanism
The lysate presents bacterial antigens and Toll-like receptor ligands to gut associated lymphoid tissue, raising mucosal IgA and priming innate defences that also operate in the urinary tract. It is broad immunostimulation, not strain specific immunity.
receptor fingerprint
Innate immune pattern-recognition receptors (TLR-mediated activation by E. coli-derived muramyl dipeptide, porin protein I and lipopeptide components)Agonist / immunostimulant
Mucosal IgA response (Peyer's patch / gut-associated lymphoid tissue)Induction
Regulatory T cell / oral tolerance pathwayInduction (hypothesised)
Safetyrisks and cautions, not medical advice
a licensed bacterial lysate immunostimulant, prescription-only in the European countries that register it and not licensed at all in the US
Subjective profileweighing the evidence above
Of all the oral immunostimulants sold for infection, this is the one mainstream urology actually takes seriously, and recurrent urinary tract infection badly needs an option that is not another round of antibiotics. Expect fewer recurrences rather than an end to them; it is a preventive course run over months and it does nothing at all for an infection already burning. Recurrence in a man, blood in the urine, or fever with flank pain points at something structural and needs investigating before any preventive is worth starting.
Where to buy
Suppliers
Vendors carrying Uro-Vaxom, with live product details and codes. Links are affiliate links that support the wiki at no cost to you.
RUPharma🌐
Uro-Vaxom
Research
- 1997first citedStudies on the immunogenicity of an Escherichia coli extract after oral application in mice
- 2008meta-analysisImmunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis
- 2015most recentOral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systemat…
- 1.Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis
- 2.Oral vaccine (OM-89) in the recurrent urinary tract infection prophylaxis: a realistic systematic review with meta-analysis
- 3.Immunostimulatory properties of the bacterial extract OM-89 in vitro and in vivo
- 4.Studies on the immunogenicity of an Escherichia coli extract after oral application in mice
- 5.An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis
5 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
Notes and cautions
- There is no boxed warning and the tolerability record is good; the meta-analyses report no safety signal that would offset the benefit, and adverse effects are typically mild gastrointestinal upset, headache or rash.
- The honest caution is about evidence rather than harm: the trial base is small, old, of low methodological quality, follow-up stops at six months, and industry involvement was not declared in any of the usable studies [2].
- It should be presented as an antibiotic-sparing option supported by low-quality but consistently positive evidence, not as a proven prophylactic.
- It is an immunostimulant and should be used cautiously in anyone on immunosuppressive therapy or with an autoimmune condition.